Boothbay Fund Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-7,000
Closed -$1.49M 1760
2024
Q3
$1.49M Buy
+7,000
New +$1.79M 0.03% 620
2024
Q2
Sell
-14,800
Closed -$3.95M 1738
2024
Q1
$3.95M Buy
+14,800
New +$3.49M 0.08% 302
2023
Q1
Sell
-82,000
Closed -$23.8M 2367
2022
Q4
$23.8M Buy
82,000
+12,400
+18% +$1.21M 0.55% 11
2022
Q3
$4.52M Buy
+69,600
New +$4.84M 0.11% 219
2020
Q1
Sell
-191
Closed -$1.74M 972
2019
Q4
$1.74M Hold
191
0.15% 186
2019
Q3
$1.65M Sell
191
-96
-33% -$9.01K 0.15% 185
2019
Q2
$3.01M Buy
+287
New +$30.7K 0.27% 88
2018
Q4
Sell
-57
Closed -$1.22M 788
2018
Q3
$1.22M Buy
+57
New +$14.3K 0.12% 163

Other funds holding MDGL

Boothbay Fund Management's MDGL Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 1,857 shares worth $997K. The stake represents 0.01% of the portfolio and ranks #1092 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in MDGL as recently as Q3 2025.

Boothbay Fund Management first reported a position in MDGL in Q1 2019 and has held it in 13 quarters since. The position peaked at $2.18M in Q2 2020. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Boothbay Fund Management held 1,857 shares of Madrigal Pharmaceuticals worth $997K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Boothbay Fund Management position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1092 holding.
  • Boothbay Fund Management first reported a position in Madrigal Pharmaceuticals in Q1 2019 and has held it in 13 quarters since.
  • Boothbay Fund Management's Madrigal Pharmaceuticals position peaked at $2.18M in Q2 2020.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.